Biomarin

BioMarin Isn't a "Gene Therapy Company"
BioMarin Isn't a "Gene Therapy Company"
Motley Fool
Biomarin
earnings
Flag link:
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Concert Pharmaceuticals
Horizon Pharma
Edwards Lifesciences
Zimmer Biomet
Genfit
Precision Biosciences
Boston Scientific
AbbVie
Alexion
Bristol-Myers Squibb
Baxter
Biomarin
AtriCure
Biogen
Seattle Genetics
IPOs
earnings
Flag link:
AbbVie, Akcea benefit from latest CHMP recommendations
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Europe
CHMP
AbbVie
Akcea
Biomarin
Sanofi
Pfizer
drug approvals
Flag link:
Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Yahoo/Guru Focus
M&A
Merck
Biogen
Biomarin
Eli Lilly
Bristol-Myers Squibb
Flag link:
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Flag link:
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:
3 Biotech Stocks With Virtual Monopolies
3 Biotech Stocks With Virtual Monopolies
Motley Fool
Alexion Pharmaceuticals
Biomarin
Vertex Pharmaceuticals
Flag link:
Express Scripts staking out million-dollar gene therapies
Express Scripts staking out million-dollar gene therapies
Reuters
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
Flag link:
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
Motley Fool
Biomarin
earnings
Flag link:
BioMarin Begins Pediatric Study on Achondroplasia Candidate
BioMarin Begins Pediatric Study on Achondroplasia Candidate
Yahoo/Zacks.com
Biomarin
clinical trials
vosoritide
achrondoplasia
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
CP Wire
Biomarin
Palynziq
PKU
FDA
Flag link:
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
Biomarin
Palynziq
PKU
Flag link:
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
Motley Fool
Biomarin
pegvaliase
PKU
FDA
Flag link:
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints
Biomarin
hemophilia A
valrox
Flag link:
BioMarin Cruises While It Waits on Seventh Approval
BioMarin Cruises While It Waits on Seventh Approval
Motley Fool
Biomarin
pegvaliase
FDA
PKU
earnings
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
[video]ASH 2017 Recap: These Were the Big Winners and Losers
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
Flag link:

Pages